Peptide Inhibitor for Treating Inflammatory Autoimmune Diseases and Inflammatory Cancers


Growth arrest and DNA-damage-inducible protein GADD45 alpha (Gadd45a) is a protein involved in the p38 MAP kinase signaling pathway.  Inventors at the NCI have developed a 15 amino acid peptide fragment of Gadd45a that retains the functionality of Gadd45a by inhibiting enzymatic activity of tyrosine-323-phosphorylaled p38 in vitro.  The peptide is modified to make it cell permeable and exhibits minimal toxicity in vitro.  The fragment readily penetrates T cells to inhibit (a) proliferation in response to T cell receptor-mediated stimulation; (b) skewing of T cells to Th I and Th 17 cells; and (c) inflammatory cytokine production.  As a result, this fragment has anti-inflammatory properties and has potential as a therapeutic for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.



Potential Commercial Applications: Competitive Advantages:
  • Treatment for inflammatory autoimmune conditions or inflammatory cancers, such as pancreatic cancer.
 
  • Minimal cellular toxicity


Development Stage:
Discovery (Lead Identification)

Inventors:

Jonathan Ashwell (NCI)  ➽ more inventions...


Intellectual Property:

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-281-2012
Updated: Sep 6, 2016